Record-Breaking Price Movement
On 17 Aug 2026, Fredun Pharmaceuticals Ltd’s share price surged to an intraday high of Rs.1600, representing a 3.38% increase from the previous close. The stock opened with a gap up of 3.37%, signalling strong buying interest at the start of the trading session. Despite a slight intraday dip to Rs.1505, the price closed near its peak, registering a modest day change of 0.15%. This performance contrasts with the broader Sensex, which declined by 0.42% on the same day, underscoring Fredun’s relative strength.
Strong Technical Positioning
The stock is trading comfortably above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing a bullish technical trend. The overall technical outlook remains positive, with multiple indicators such as MACD, Bollinger Bands, and KST signalling bullish momentum on both weekly and monthly timeframes. The stock’s immediate support is anchored at Rs.343.33, its 52-week low, while the recent breakthrough of the Rs.1600 level sets a new benchmark for resistance.
Exceptional Long-Term Performance
Fredun Pharmaceuticals Ltd has demonstrated extraordinary returns over various time horizons. The stock has delivered a staggering 344.08% return over the past year, vastly outperforming the Sensex’s negative 3.62% return during the same period. Year-to-date, the stock has appreciated by 194.63%, while its three-year performance stands at an impressive 366.60%, compared to the Sensex’s 19.24%. Over five years, the stock’s growth has been even more pronounced, with a phenomenal 1072.77% increase, dwarfing the Sensex’s 39.24% gain.
Robust Financial Growth Underpinning the Rally
The company’s strong stock performance is supported by solid financial fundamentals. Fredun Pharmaceuticals has achieved a healthy compound annual growth rate (CAGR) in net sales of 34.99% over five years, accompanied by an operating profit growth of 62.66%. The latest quarterly results for June 2026 were outstanding, with net profit surging by 94.53%. The company has maintained positive results for nine consecutive quarters, reflecting consistent operational strength.
In the nine months ending June 2026, the company reported a profit after tax (PAT) of Rs.34.72 crores, marking an 81.12% increase year-on-year. Profit before tax excluding other income (PBT less OI) for the quarter stood at Rs.20.55 crores, growing by an impressive 127.32%. Operating cash flow for the year reached a peak of Rs.16.44 crores, highlighting strong cash generation capabilities.
Valuation and Quality Metrics
Fredun Pharmaceuticals is classified as a micro-cap stock with a Mojo Score of 77.0 and a current Mojo Grade of Buy, revised from Strong Buy on 12 Aug 2026. The stock’s valuation multiples reflect a premium positioning, with a price-to-earnings (P/E) ratio of 58x and a price-to-book value (P/BV) of 9.18x. Enterprise value to EBITDA stands at 24.56x, while EV to capital employed is 6.23x. The PEG ratio of 0.92x suggests that the stock’s price growth is broadly in line with its earnings growth, indicating a balanced valuation perspective.
Dividend metrics show a modest yield of 0.03%, with a recent dividend payout of Rs.0.233 per share declared on 23 Jun 2026. The company maintains a low dividend payout ratio of 1.15%, consistent with its growth-oriented profile.
Quality assessments rate Fredun Pharmaceuticals as an average quality company based on long-term financial performance. Key strengths include excellent growth rates and no promoter share pledging. However, the company carries moderate leverage, with an average debt to EBITDA ratio of 2.93 and a net debt to equity ratio of 0.56. Return on capital employed (ROCE) averages 15.49%, reflecting efficient capital utilisation, while return on equity (ROE) is relatively weaker at 12.48%.
Market-Beating Returns and Delivery Volumes
The stock’s market-beating performance is evident not only in price appreciation but also in delivery volumes. Over the past month, delivery volumes have increased by 266.71%, with the latest trading day recording 62.48% of total volume as delivery, surpassing the five-day average of 54.42%. This indicates sustained investor participation in the stock’s upward trajectory.
Summary of Key Financial Trends
Fredun Pharmaceuticals’ short-term financial trend as of June 2026 is classified as outstanding. The company’s operating profit to interest coverage ratio reached a high of 3.80 times in the latest quarter, while quarterly profit before depreciation, interest, and taxes (Pbdit) hit a record Rs.32.74 crores. Net sales for the nine-month period stood at Rs.602.23 crores, with the debt-equity ratio improving to a low of 0.80 times, signalling prudent financial management.
Interest expenses have increased by 26.42% over the last six months, reaching Rs.23.11 crores, a factor to monitor in the context of the company’s overall financial health.
Conclusion
Fredun Pharmaceuticals Ltd’s stock reaching an all-time high of Rs.1600 on 17 Aug 2026 marks a significant milestone reflecting the company’s robust financial performance, strong growth trajectory, and favourable technical indicators. The stock’s sustained outperformance relative to the broader market and sector benchmarks underscores its resilience and the strength of its underlying fundamentals. While valuation metrics suggest a premium, the company’s consistent earnings growth and cash flow generation provide a solid foundation for its current market valuation.
